Evaluation of clinical manifestations, health risks, and quality of life among women with polycystic ovary syndrome

Autoři: Syeda Sidra aff001;  Muhammad Haseeb Tariq aff002;  Muhammad Junaid Farrukh aff003;  Muhammad Mohsin aff001
Působiště autorů: Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan aff001;  Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia aff002;  Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia aff003
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0223329


This study aimed to evaluate the clinical manifestations and health risks associated with polycystic ovary syndrome (PCOS) and its impact on quality of life (QOL) in Pakistan. A detailed cross-sectional study was conducted on PCOS among women of reproductive age visiting the gynecology and obstetrics and endocrinology departments at primary and tertiary care hospitals located in Abbottabad, Kohat, and Islamabad. In total, 440 patients meeting the inclusion criteria were included. A checklist was specifically designed to identify symptoms and health risks, including adverse drug reactions, complications, irrational prescription or underprescription, and drug–drug interactions. The Short Form-12 questionnaire was used to evaluate the QOL of patients with PCOS. Data collected were analyzed for descriptive and inferential statistics using chi-square test, analysis of variance, and post hoc analysis. All patients exhibited the cardinal symptoms of PCOS, including obesity (n = 352, 80%), acne (n = 296, 67.3), hirsutism (n = 299, 68%), hyperglycemia (n = 278, 63.2%), and irregular menstruation (n = 316, 71.8%). Ultrasonography confirmed that 268 (61%) patients had multiple cysts of >10 mm in diameter. Patients with untreated PCOS exhibited a high prevalence of health risks including hypertension (n = 87, 19.8%), diabetes (n = 268, 60.9%), sleep apnea (n = 11, 2.5%), infertility (n = 146, 33.2%), increased endometrial thickness (n = 21, 4.8%), miscarriages (n = 68, 15.5%), high cholesterol level (n = 85, 19.3%), and hyperandrogenism (n = 342, 77.7%). Most patients exhibited low QOL scores (n = 374, 85%), with depression being the largest contributor to low QOL. Apart from novel results, this study found an association between depression and low QOL in patients with PCOS, suggesting the need for reviewing the management guidelines and psychological health assessment of women with PCOS.

Klíčová slova:

Adverse reactions – Depression – Obesity – Polycystic ovary syndrome – Quality of life – Infertility – Acne


1. Dargham SR, Ahmed L, Kilpatrick ES, Atkin SL. The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population. PloS One. 2017;12: e0181467. doi: 10.1371/journal.pone.0181467 28723965

2. Khomami MB, Tehrani FR, Hashemi S, Farahmand M, Azizi F. Of PCOS symptoms, hirsutism has the most significant impact on the quality of life of Iranian women. PLoS One. 2015;10: e0123608. doi: 10.1371/journal.pone.0123608 25874409

3. Akram M, Roohi N. Endocrine correlates of polycystic ovary syndrome in Pakistani women. J Coll Physicians Surg Pak. 2015;25: 22–26. 25604364

4. Mulders AG, Laven JS, Eijkemans MJ, de Jong FH, Themmen AP, Fauser BC. Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod. 2004;19: 2036–2042. doi: 10.1093/humrep/deh373 15217995

5. Navaratnarajah R, Pillay OC, Hardiman P. Polycystic ovary syndrome and endometrial cancer. Semin Reprod Med. 2008;26: 62–71. doi: 10.1055/s-2007-992926 18181084

6. Hung JH, Hu LY, Tsai SJ, Yang AC, Huang MW, Chen PM, et al. Risk of psychiatric disorders following polycystic ovary syndrome: a nationwide population-based cohort study. PloS One. 2014;9: e97041. doi: 10.1371/journal.pone.0097041 24816764

7. Brady C, Mousa SS, Mousa SA. Polycystic ovary syndrome and its impact on women's quality of life: More than just an endocrine disorder. Drug Healthc Patient Saf. 2009;1: 9–15. 21701605

8. Dumesic DA, Akopians AL, Madrigal VK, Ramirez E, Margolis DJ, Sarma MK, et al. Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab. 2016;101: 4178–4188. doi: 10.1210/jc.2016-2586 27571186

9. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333: 853–861. doi: 10.1056/NEJM199509283331307 7651477

10. Christakou CD, Diamanti-Kandarakis E. Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome. Womens Health (Lond). 2008;4: 583–594. doi: 10.2217/17455057.4.6.583 19072461

11. Zhu Q, Zhou H, Zhang A, Gao R, Yang S, Zhao C, et al. Serum LBP is associated with insulin resistance in women with PCOS. PloS One. 2016;11: e0145337. doi: 10.1371/journal.pone.0145337 26799617

12. Akram M, Roohi N. Endocrine correlates of polycystic ovary syndrome in Pakistani women. J Coll Physicians Surg Pak. 2015;25: 22–26. 25604364

13. Carmina E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva Ginecol. 2004;56: 1–6. 14973405

14. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31: 2841–2855. doi: 10.1093/humrep/dew218 27664216

15. Zawadzski J. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992. pp. 377–384.

16. Hsu MI, Liou TH, Chou SY, Chang CY, Hsu CS. Diagnostic criteria for polycystic ovary syndrome in Taiwanese Chinese women: comparison between Rotterdam 2003 and NIH 1990. Fertility Steril. 2007;88: 727–729.

17. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98: 4565–4592. doi: 10.1210/jc.2013-2350 24151290

18. Greenwood EA, Pasch L, Legro RS, Cedars M, Huddleston H. Quality of life and depression in polycystic ovary syndrome. Fertil Steril. 2017;108: e64–e65.

19. Stefanaki C, Bacopoulou F, Livadas S, Kandaraki A, Karachalios A, Chrousos GP, et al. Impact of a mindfulness stress management program on stress, anxiety, depression and quality of life in women with polycystic ovary syndrome: a randomized controlled trial. Stress. 2015;18: 57–66. doi: 10.3109/10253890.2014.974030 25287137

20. Brewer M, Pawelczak M, Kessler M, Shah B. A review of polycystic ovarian syndrome in adolescents. Minerva Pediatr. 2010;62: 459–473. 20940680

21. Fosgate GT. Practical sample size calculations for surveillance and diagnostic investigations. J Vet Diagn Invest. 2009;21: 3–14. doi: 10.1177/104063870902100102 19139495

22. Bergström E, Blomquist HK. Is the prevalence of overweight and obesity declining among 4-year-old Swedish children? Acta Paediatr. 2009;98: 1956–1958. doi: 10.1111/j.1651-2227.2009.01490.x 19735498

23. Staff P. Physicians’ desk reference. PDR Network. 2011.

24. Preston CL. Stockley’s drug interactions. 11th edition. London: Pharmaceutical Press; 2015.

25. Dovom MR, Tehrani FR, Djalalinia S, Cheraghi L, Gandavani SB, Azizi F. Menstrual cycle irregularity and metabolic disorders: a population-based prospective study. PloS One. 2016;11: e0168402. doi: 10.1371/journal.pone.0168402 27992506

26. Teede HJ, Joham AE, Paul E, Moran LJ, Loxton D, Jolley D, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity. 2013;21: 1526–1532. doi: 10.1002/oby.20213 23818329

27. Singh A, Gnanalingham K, Casey A, Crockard A. Quality of life assessment using the Short Form-12 (SF-12) questionnaire in patients with cervical spondylotic myelopathy: comparison with SF-36. Spine. 2006;31: 639–643. doi: 10.1097/01.brs.0000202744.48633.44 16540866

28. Benson S, Hahn S, Tan S, Mann K, Janssen O, Schedlowski M, et al. Prevalence and implications of anxiety in polycystic ovary syndrome: results of an internet-based survey in Germany. Hum Reprod. 2009;24: 1446–1451. doi: 10.1093/humrep/dep031 19223290

29. Misbah Malik NT, Mahmud G. Effect of metformin alone compared with metformin plus simvastatin on polycystic ovarian syndrome in Pakistani women. J Coll Physicians Surg Pak. 2018;28: 184–187. doi: 10.29271/jcpsp.2018.03.184 29544572

30. Riaz M, Basit A, Fawwad A, Ahmadani MY, Zafar A, Miyan Z. Frequency of insulin resistance in patients with polycystic ovary syndrome: A study from Karachi, Pakistan. Pak J Med Sci. 2010;26: 791–794.

31. Laganà AS, Garzon S, Casarin J, Franchi M, Ghezzi F. Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach. Trends Endocrinol Metab. 2018;29: 768–780. doi: 10.1016/j.tem.2018.09.001 30270194

32. Januszewski M, Issat T, Jakimiuk AA, Santor-Zaczynska M, Jakimiuk AJ. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol Pol. 2019;90: 7–10. doi: 10.5603/GP.2019.0002 30756365

33. Laganà AS, Rossetti P, Sapia F, Chiofalo B, Buscema M, Valenti G, et al. Evidence-based and patient-oriented inositol treatment in polycystic ovary syndrome: changing the perspective of the disease. Int J Endocrinol Metab. 2017;15: e43695. doi: 10.5812/ijem.43695 28835764

34. Reyes-Muñoz E, Sathyapalan T, Rossetti P, Shah M, Long M, Buscema M, et al. Polycystic ovary syndrome: implication for drug metabolism on assisted reproductive techniques—a literature review. Adv Ther. 2018;35: 1805–1815. doi: 10.1007/s12325-018-0810-1 30311070

35. Di Paola R, Garzon S, Giuliani S, Laganà AS, Noventa M, Parissone F, et al. Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman’s age and markers of ovarian reserve. Arch Gynecol Obstet. 2018;298: 1029–1035. doi: 10.1007/s00404-018-4906-2 30242498

36. Domecq JP, Prutsky G, Mullan RJ, Sundaresh V, Wang AT, Erwin PJ, et al. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98: 4646–4654. doi: 10.1210/jc.2013-2374 24092830

37. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84: 1897–1899. doi: 10.1210/jcem.84.6.5803 10372683

38. Chiofalo B, Laganà AS, Palmara V, Granese R, Corrado G, Mancini E, et al. Fasting as possible complementary approach for polycystic ovary syndrome: Hope or hype? Med Hypotheses. 2017;105: 1–3. doi: 10.1016/j.mehy.2017.06.013 28735644

39. Asemi Z, Samimi M, Taghizadeh M, Esmaillzadeh A. Effects of Ramadan fasting on glucose homeostasis, lipid profiles, inflammation and oxidative stress in women with polycystic ovary syndrome in Kashan, Iran. Arch Iran Med. 2015;18: 806–810. 26621011

40. Akbar MF, MedSc M, Rizkinov M, Jumsa MD. The impact of Ramadhan fasting in women with PCOS: an association between FPG and lipid profiles. Arch Iran Med. 2016;19: 308.

41. Zehra S, Arif A, Anjum N, Azhar A, Qureshi M. Depression and anxiety in women with polycystic ovary syndrome from Pakistan. Life Sci J. 2015;12: 1–4.

42. Rasgon NL1, Rao RC, Hwang S, Altshuler LL, Elman S, Zuckerbrow-Miller J, et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord. 2003;74: 299–304. doi: 10.1016/s0165-0327(02)00117-9 12738050

43. Barnard L, Ferriday D, Guenther N, Strauss B, Balen A, Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Human Reprod. 2007;22: 2279–2286.

44. Moghadam ZB, Fereidooni B, Saffari M, Montazeri A. Polycystic ovary syndrome and its impact on Iranian women’s quality of life: a population-based study. BMC Womens Health. 2018;18: 164. doi: 10.1186/s12905-018-0658-1 30305063

45. Amer SA, Smith J, Mahran A, Fox P, Fakis A. Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome. Hum Reprod. 2017;32: 1631–1638. doi: 10.1093/humrep/dex227 28854590

46. Al-Obaidi MT, Ali ZH, Al-Saadi WI, Al-Wasiti EA, Al-Aubaidy H. Impact of letrozole versus clomiphene citrate on endometrial receptivity in Iraqi women with polycystic ovarian syndrome. J Clin Pharm Ther. 2019. doi: 10.1111/jcpt.12831 30868612

47. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90: 1929–1935. doi: 10.1210/jc.2004-1045 15623819

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden